Genetic screening for haematological cancers

Screening for haematological cancers is costly and time-consuming. The standard screening procedure, which looks for mutations in four specific genes, costs about $300 and can take seven to 10 days to return complete results. To allay the costs involved, many hospitals wait for a batch of samples from multiple patients before running the test. Precipio, based in New Haven, has now advanced the state of care with the commercial launch of HemeScreen, a novel proprietary test for mutations in haematological cancers.

Importantly, the HemeScreen assay can deliver results in four to six hours rather than days, enabling a same-day turnaround time. Equally important, the HemeScreen assay also costs a fraction of the current technologies to run. At $100, this is about one-third of the cost of the traditional method, making the potential savings substantial.

 

Other news

Visualise No Malaria

Upcoming Events

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

Ist International Blizard/QMUL Tuberculosis Symposium

Bearsted Lecture Theatre, Alexandra Wing, Queen Mary University of London - Whitechapel
26-27 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Apr 2019

Reducing exposure to antimicrobial agents

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.